Gene · 57721
NIH grants1,078
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 1,078
Download this page as JSON| Grant | Title | METTL14 papers | Newest fiscal year |
|---|---|---|---|
| R01AI189220 | How SAMHD1 regulates HIV-1 innate immunity and viral gene expression | 1 | 2025 |
| R01CA159859 | Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma | 1 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 1 | 2025 |
| R01CA205247 | Targeting MicroRNAs to Eradicate Leukemia Stem Cells | 1 | 2025 |
| R01CA219541 | Epigenetic Mechanisms of Biliary Epithelial Neoplasia | 1 | 2025 |
| R01CA225958 | Novel bioengineered microRNA therapeutics for lung cancer | 1 | 2025 |
| R01CA228700 | Epstein-Barr virus LMP1 mediated oncogenicity | 1 | 2025 |
| R01CA236356 | Protein arginine methylation in breast cancer | 1 | 2025 |
| R01CA250534 | Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer | 1 | 2025 |
| R01CA257520 | A deubiquitination module controls Treg adaptation to tumor microenvironment | 1 | 2025 |
| R01CA263506 | MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response | 1 | 2025 |
| R01CA265095 | Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | 1 | 2025 |
| R01CA266600 | EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA | 1 | 2025 |
| R01CA268998 | Tumor suppressor reprogramming by EBV through post-translational modification | 1 | 2025 |
| R01CA271486 | Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis | 1 | 2025 |
| R01CA271498 | Next Generation Rat Models of ER+ Breast Cancer | 1 | 2025 |
| R01CA271915 | Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer | 1 | 2025 |
| R01CA278812 | Citrulline-urea cycle in KSHV cellular transformation | 1 | 2025 |
| R01CA280389 | TET2-mediated epitranscriptomic regulation in leukemia microenvironment | 1 | 2025 |
| R01CA282939 | Understanding and Targeting the R-Loop-Mediated DNA Damage Response at Telomeres | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/grants?page=9